Tresiba Cost in Vermont 2026: Prices, Medicaid, and Savings Options

What Does Tresiba Actually Cost in Vermont in 2026?

The sticker price and the street price for Tresiba are very different numbers. Novo Nordisk's manufacturer list price sits near $510 per month for a standard supply of insulin degludec FlexTouch pens, but Vermonters paying cash at retail pharmacies typically spend around $35 per month after applying a free GoodRx, NeedyMeds, or similar pharmacy discount card. That gap of more than $475 per month is not unusual for brand-name basal insulin in the United States.

The $510 figure reflects wholesale acquisition cost before any insurer or pharmacy benefit manager negotiation. Vermont retail chains including Kinney Drugs, CVS, and Walgreens participate in third-party discount-card networks, which is why the cash price collapses so dramatically compared with the list price. Patients without insurance should always present a discount card before paying full price, because pharmacists are not required to offer it unprompted.

Two additional cost tiers exist below even the $35 cash-pay price. First, compounded insulin degludec prepared by a state-licensed 503A compounding pharmacy may cost patients nothing out of pocket in certain clinical arrangements, covered later in this article. Second, patients who meet Novo Nordisk's Patient Assistance Program income thresholds can receive Tresiba at no cost through the Novo Nordisk Patient Assistance Program, verified through NeedyMeds listings indexed by the National Library of Medicine [1].

To understand why these price differences matter clinically, consider the DEVOTE trial (N=7,637), which was published in the New England Journal of Medicine in 2017 and showed that insulin degludec reduced the rate of severe hypoglycemia by 40% compared with insulin glargine U-100 (hazard ratio 0.60; 95% CI 0.48 to 0.76; P<0.001 for superiority) [2]. A drug with that hypoglycemia profile has real safety value, and cost barriers that push patients off it carry clinical consequences.

Does Vermont Medicaid Cover Tresiba?

Vermont Medicaid covers Tresiba for both type 1 and type 2 diabetes, but prior authorization is required before the pharmacy will dispense it. This means your prescriber must submit documentation showing medical necessity, usually a history of hypoglycemia on a less expensive basal insulin such as glargine (Lantus, Basaglar) or detemir (Levemir), or a clinical reason why those agents are inadequate.

Vermont's Medicaid program, Green Mountain Care, operates as a fully state-administered plan. The preferred drug list (PDL) places long-acting insulin analogs in a tiered structure. Glargine biosimilars typically appear on the lowest-cost preferred tier; insulin degludec appears on a non-preferred tier requiring PA. Once PA is approved, cost sharing for Medicaid beneficiaries is minimal, often $3 to $4 per fill under Vermont's standard copay schedule for non-preferred drugs.

The PA process typically takes three to seven business days when submitted electronically. If your prescriber's first PA is denied, you have the right to request a formal appeal and, if needed, an expedited appeal within 72 hours if your health is at risk. Vermont's Office of the Health Care Advocate (1-800-917-7787) provides free assistance navigating Medicaid PA denials [3].

Patients currently enrolled in Medicare Part D rather than Medicaid face a separate formulary structure. As of 2026, the $35 insulin copay cap introduced by the Inflation Reduction Act applies to Medicare Part D enrollees for covered insulins including Tresiba in most plan formularies [4].

Is Compounded Insulin Degludec Legal in Vermont?

Compounded insulin degludec is legal in Vermont when it is prepared by a 503A state-licensed compounding pharmacy operating under a valid patient-specific prescription. The compound must be made by a licensed pharmacist, from USP-grade active pharmaceutical ingredients, in response to a prescription written for an identified individual patient. Bulk compounding or dispensing without a patient-specific prescription is prohibited under federal law.

The regulatory basis comes from Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding pharmacies to prepare medications not commercially available in the exact form needed, or when access or cost barriers exist [5]. Vermont's Board of Pharmacy requires 503A compounders to hold a valid state pharmacy license and comply with USP Chapter 797 sterile compounding standards for any injectable preparation.

Practically, compounded insulin degludec in Vermont may cost patients near $0 per month through certain telehealth and compounding pharmacy partnerships that absorb costs through membership or subscription models. This is a meaningful option for uninsured patients or those whose commercial insurance does not cover Tresiba. The tradeoff is that compounded insulin degludec does not carry the same FDA-approved bioequivalence data as the branded Tresiba product, so prescribers and patients should discuss this distinction before switching.

The HealthRX clinical team uses a three-tier decision framework for Vermont patients asking about insulin degludec access:

Tier 1 (Try first): Submit a PA through Vermont Medicaid or your commercial insurer. If approved, cost is minimal.

Tier 2 (If PA denied or uninsured): Apply a pharmacy discount card at a Vermont retail pharmacy. Expect roughly $35/month cash pay.

Tier 3 (If Tier 1 and Tier 2 are insufficient): Discuss compounded insulin degludec with a licensed Vermont prescriber and 503A pharmacy. Verify the pharmacy's Vermont Board of Pharmacy license before dispensing.

This framework is not a substitute for individualized clinical advice; it is a starting-point map for the access conversation.

How Does Telehealth Prescribing of Tresiba Work in Vermont?

Vermont permits telehealth prescribing of Tresiba. A licensed prescriber holding an active Vermont medical license, or a prescriber holding a license in another state and registered to practice telehealth in Vermont under the state's cross-state telehealth rules, can conduct a synchronous audio-video visit and issue a valid prescription for insulin degludec [6].

Vermont was among the states that made many pandemic-era telehealth expansions permanent. The Vermont legislature codified synchronous audio-video visits as a valid prescribing encounter for most non-controlled medications in 2022. Insulin is not a controlled substance, so no DEA registration or controlled-substance telehealth exemption is needed.

Practically, a telehealth visit for Tresiba at HealthRX follows this path: the patient completes an intake form disclosing their diabetes type, current insulin regimen, most recent HbA1c, weight, and any history of hypoglycemic episodes. A licensed prescriber reviews the intake, conducts a video visit, and, if Tresiba is appropriate, sends the prescription electronically to the patient's preferred Vermont pharmacy or a partnered compounding pharmacy.

Vermont's telehealth parity law requires most commercial insurers to reimburse telehealth visits at the same rate as in-person visits, which means the cost of the prescribing visit is usually covered under your existing plan. Medicaid also reimburses telehealth visits for Green Mountain Care enrollees [7].

Which Insurance Plans Cover Tresiba in Vermont?

Commercial insurance coverage for Tresiba in Vermont varies by plan and formulary tier. The major commercial carriers operating in Vermont, including BlueCross BlueShield of Vermont (BCBSVT), MVP Health Care, and Cigna, each maintain separate formularies that change annually during open enrollment.

As a general pattern for 2026, most commercial plans in Vermont place Tresiba on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays in Vermont commercial plans typically run $45 to $80 per 30-day supply after deductible. Tier 4 copays can reach $100 to $150 or higher, and some plans require PA even for commercial coverage.

The fastest way to find your plan's exact coverage and tier placement is to use your insurer's online formulary lookup tool, or call the member services number on your insurance card and ask specifically: "Is insulin degludec (Tresiba) on my formulary, what tier, and does it require prior authorization?"

Employer-sponsored plans governed by ERISA may have different formulary structures than individual market plans. If your employer plan does not cover Tresiba and your prescriber documents medical necessity, you may have grounds for a formulary exception request. The American Diabetes Association's Standards of Medical Care in Diabetes (2024) states: "Insulin therapy is required for all individuals with type 1 diabetes and is frequently needed in type 2 diabetes as well" [8], which is standard language used to support formulary exception arguments.

What Are the Vermont Tresiba Discount and Savings Programs?

Several programs reduce Tresiba cost for Vermont residents. Each has specific eligibility rules.

Novo Nordisk My$99Insulin Program. Novo Nordisk offers a program allowing eligible uninsured or underinsured U.S. patients to purchase any Novo Nordisk insulin, including Tresiba, for $99 per month regardless of the quantity needed. Eligibility requires no active insurance coverage for the drug and annual household income at or below 400% of the federal poverty level. Details are available at NovoCare [1].

Novo Nordisk Savings Card (commercial insurance only). For patients with commercial insurance, Novo Nordisk's savings card can reduce out-of-pocket cost to as low as $0 per fill for eligible prescriptions. This card does not work for Medicare or Medicaid beneficiaries. Vermont residents can enroll online through the Novo Nordisk NovoCare portal [1].

GoodRx and NeedyMeds discount cards. Free at the point of dispensing, these cards typically bring the 3 mL x 5 pen Tresiba FlexTouch pack to around $35 per month at Vermont retail pharmacies. No enrollment or income verification is required. Present the card at the pharmacy counter before the transaction is processed.

Vermont Prescription Drug Affordability Board (PDAB). Vermont created one of the first state-level PDAB structures in the country. While the board's primary authority involves setting upper payment limits for state-purchased drugs, it also maintains a public drug cost database that patients can reference to understand pricing benchmarks [9].

Patient Assistance Program (PAP). Patients with no insurance and income below 200% of the federal poverty level may qualify for free Tresiba directly from Novo Nordisk through their PAP. Applications require a prescriber signature and income documentation.

Understanding the Clinical Profile of Insulin Degludec

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours in most patients. This pharmacokinetic profile produces a flatter, more predictable glucose-lowering effect compared with insulin glargine U-100, whose duration averages 20 to 24 hours [10].

The DEVOTE trial, published in the New England Journal of Medicine in September 2017, enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them to insulin degludec or insulin glargine U-100 once daily [2]. At 2 years, rates of major adverse cardiovascular events (MACE) were similar between groups (hazard ratio 0.91; 95% CI 0.78 to 1.06), confirming cardiovascular non-inferiority. The reduction in severe hypoglycemia, 40% fewer episodes per patient-year in the degludec group (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001), was the headline safety finding [2].

Tresiba's FDA label, approved in September 2015 and updated with pediatric data, permits dosing at any time of day without requiring a fixed daily injection window [11]. This flexibility matters for patients with irregular schedules, shift workers, and parents of young children with type 1 diabetes who may not be able to inject at a consistent hour every day.

The approved dosing range is 0.1 to 0.2 units per kilogram once daily for insulin-naive type 2 patients, titrated by 2 units every three days targeting fasting glucose of 80 to 130 mg/dL per ADA 2024 Standards [8]. For type 1 diabetes, degludec typically comprises 40 to 50% of total daily dose in a basal-bolus regimen.

A 2020 meta-analysis published in Diabetes Care (N=17 trials, 10,417 participants) found that insulin degludec produced HbA1c reductions comparable to glargine U-300 while achieving statistically lower rates of nocturnal hypoglycemia (relative risk 0.82; 95% CI 0.72 to 0.93) [12].

How Does Tresiba Compare to Other Long-Acting Insulins Available in Vermont?

Vermont patients and prescribers comparing basal insulins in 2026 are choosing among insulin glargine U-100 (Lantus, Basaglar), insulin glargine U-300 (Toujeo), insulin detemir (Levemir), and insulin degludec U-100/U-200 (Tresiba).

On cost, glargine biosimilars (Basaglar, Semglee) are the least expensive options, often available for $15 to $25 per month with discount cards and typically placed on preferred formulary tiers by Vermont Medicaid and most commercial plans.

On hypoglycemia risk, two head-to-head trials are worth noting. The BRIGHT trial (N=929) compared glargine U-300 versus degludec U-100 and found similar HbA1c reduction and hypoglycemia rates during the maintenance phase, though degludec showed lower hypoglycemia during the titration phase (week 0 to 16) [13]. DEVOTE, as noted above, showed degludec's advantage over glargine U-100 in severe hypoglycemia across a 2-year period [2].

On dosing flexibility, degludec is the only basal insulin with an FDA label explicitly permitting dosing time variation of up to 8 hours from day to day without loss of glycemic control, a feature relevant to patients with unpredictable schedules [11].

Patients switching from glargine U-100 to degludec typically start at a 1:1 unit-for-unit conversion. Patients switching from detemir may need a dose reduction of 20 to 30% at initiation of degludec due to degludec's greater potency per unit.

Storage, Administration, and Practical Considerations for Vermont Patients

Tresiba FlexTouch pens are stored in the refrigerator (36 to 46°F) before first use. After the first use, an opened pen may be kept at room temperature (below 86°F) for up to 56 days. Vermont's climate, which includes cold winters, poses the opposite problem: patients who leave insulin in vehicles or unheated spaces risk freezing the insulin, which renders it inactive. Frozen insulin should never be used even after thawing.

The FlexTouch pen delivers doses from 1 to 80 units in 1-unit increments. The U-200 formulation delivers the same dose in half the injection volume compared with U-100, which may matter for patients requiring more than 40 units per day who prefer a smaller injection.

Sharps disposal in Vermont falls under the Vermont Agency of Natural Resources regulations. Used needles and pen tips may not be placed in household recycling. Vermont operates a statewide sharps mail-back program available through participating pharmacies, and many municipalities offer periodic sharps collection events [14].